GWN Securities’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-35,538
Closed -$601K – 543
2026
Q2
$601K Buy
35,538
+4,054
+13% +$56.7K 0.1% 259
2026
Q1
$404K Buy
31,484
+10,641
+51% +$136K 0.08% 286
2025
Q4
$187K Buy
20,843
+8,219
+65% +$113K 0.04% 430
2025
Q3
$218K Buy
+12,624
New +$155K 0.05% 343

Other funds holding NTLA

GWN Securities's NTLA Position: Q3 2026 in Review

GWN Securities sold out of Intellia Therapeutics (NTLA) in Q3 2026, closing a stake of 35,538 shares — an estimated $601K sold.

GWN Securities first reported a position in NTLA in Q3 2025 and held it in 4 quarters. The position peaked at $601K in Q2 2026. 271 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • GWN Securities reported no remaining Intellia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • GWN Securities sold 35,538 Intellia Therapeutics shares in Q3 2026, an estimated $601K.
  • GWN Securities first reported a position in Intellia Therapeutics in Q3 2025 and held it in 4 quarters.
  • GWN Securities's Intellia Therapeutics position peaked at $601K in Q2 2026.
  • 271 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on GWN Securities's 13F filing for Q3 2026, filed 12 Nov 2026.